Literature DB >> 15093533

A new therapeutic antibody masks ErbB2 to its partners.

Ali Badache1, Nancy E Hynes.   

Abstract

In cancer cells, the ErbB2 receptor tyrosine kinase can be activated in two ways: by overexpression or by ligand-mediated stimulation of another ErbB receptor. The ErbB2-targeting antibody trastuzumab (Herceptin) is used for treatment of metastatic breast cancer patients whose tumors overexpress ErbB2. A new structural study in this issue of Cancer Cell reveals how targeting ErbB2 with another antibody, pertuzumab (Omnitarg), prevents ligand-induced dimerization of ErbB2 with the other ErbB receptors. Pertuzumab's novel mode of action might offer additional therapeutic opportunities for treatment of tumors expressing ligand-activated ErbB2.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15093533     DOI： 10.1016/s1535-6108(04)00088-1

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  19 in total

Review 1.  Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.

Authors:  Deborah J L Wong; Sara A Hurvitz
Journal:  Ann Transl Med       Date:  2014-12

2.  Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation.

Authors:  Shannon E Telesco; Andrew Shih; Yingting Liu; Ravi Radhakrishnan
Journal:  Cancer Res J       Date:  2011

3.  High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K.

Authors:  Warapen Treekitkarnmongkol; Tuangporn Suthiphongchai
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

4.  [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.

Authors:  Mikael Persson; Vladimir Tolmachev; Karl Andersson; Lars Gedda; Mattias Sandström; Jörgen Carlsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-29       Impact factor: 9.236

5.  Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.

Authors:  Ritwik Ghosh; Archana Narasanna; Shizhen Emily Wang; Shuying Liu; Anindita Chakrabarty; Justin M Balko; Ana María González-Angulo; Gordon B Mills; Elicia Penuel; John Winslow; Jeff Sperinde; Rajiv Dua; Sailaja Pidaparthi; Ali Mukherjee; Kim Leitzel; Wolfgang J Kostler; Allan Lipton; Michael Bates; Carlos L Arteaga
Journal:  Cancer Res       Date:  2011-02-15       Impact factor: 12.701

6.  Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors:  Luca Gianni; Anna Lladó; Giulia Bianchi; Javier Cortes; Pirkko-Liisa Kellokumpu-Lehtinen; David A Cameron; David Miles; Stefania Salvagni; Andrew Wardley; Jean-Charles Goeminne; Veronica Hersberger; José Baselga
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

Review 7.  Acquired Resistance to Drugs Targeting Tyrosine Kinases.

Authors:  Steven A Rosenzweig
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

Review 8.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

9.  Interactions between anti-ErbB2 antibody A21 and the ErbB2 extracellular domain provide a basis for improving A21 affinity.

Authors:  Liang Chang; Changhai Zhou; Man Xu; Jing Liu
Journal:  J Comput Aided Mol Des       Date:  2009-12-12       Impact factor: 3.686

10.  Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.

Authors:  G Brockhoff; B Heckel; E Schmidt-Bruecken; M Plander; F Hofstaedter; A Vollmann; S Diermeier
Journal:  Cell Prolif       Date:  2007-08       Impact factor: 6.831
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.